Published in Blood Weekly, May 24th, 2007
Seth Hetherington, M.D., SVP of Clinical and Regulatory Affairs noted, "We have experienced both accomplishments and challenges in the early part of 2007. While making excellent progress in several of our programs, as earlier reported we terminated our Phase III study of senicapoc for the reduction of crisis rate in patients with sickle cell disease ("SCD") on the basis of our independent Data...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.